|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/506 | |
| A61P 7/00 | |||
| A61P 35/02 |
| (11) | Patento numeris | 2266572 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10173672.6 |
| Europos patento paraiškos padavimo data | 2006-05-02 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-12-29 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-09-21 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 676751 P | 2005-05-02 | US |
| (72) |
Manley, Paul W., CH
Mestan, Juergen, DE
Fabbro, Doriano, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | pyrimidylaminobenzamide derivative for use in the treatment of a TEL-PDGFR -induced myeloproliferative disease |
| pyrimidylaminobenzamide derivative for use in the treatment of a TEL-PDGFR -induced myeloproliferative disease |